Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

Masaki TerabeVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]

Faith C. RobertsonVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

http://orcid.org/0000-0001-7723-9501

Katharine ClarkVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

http://orcid.org/0000-0002-4668-7165

Emma De RavinVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Anja BloomVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

David J. VenzonData Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Shingo KatoVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Amer MirzaXOMA Corporation, Barkeley, CA, USA

Jay A. BerzofskyVaccine Branch and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USACorrespondence[email protected]

show all

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date